新型头孢布烯-阿维巴坦、头孢他啶-阿维巴坦及对照药物对来自美国各地门诊中心和疗养院的一组受试菌株的活性（2022 - 2024年）
Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of from outpatient centers and nursing homes across the United States (2022-2024).
作者信息
Fouad Aliaa, Bobenchik April M, Chamberland Robin, Clark Andrew E, Huse Holly K, Martin Isabella W, Mochon A Brian, Munson Erik, Sfeir Maroun M, Srodon Monica, Taylor Kimberly, Wang Yungchou, Westblade Lars F, Nicolau David P, Asempa Tomefa E
机构信息
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Department of Pathology, Division of Clinical Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
出版信息
Antimicrob Agents Chemother. 2025 May 7;69(5):e0186724. doi: 10.1128/aac.01867-24. Epub 2025 Apr 3.
Abstract
Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates ( = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent activity against cephalosporin non-susceptible isolates.
摘要
头孢布烯正在与阿维巴坦的口服前体药物联合开发。从美国11个州收集了500株门诊分离菌，采用手工肉汤微量稀释法进行药敏试验。头孢布烯的敏感率分别为64%（CLSI标准）和23%（EUCAST标准）。头孢布烯-阿维巴坦在MIC≤1µg/mL时的抑制率达到96.4%。药敏率如下：头孢泊肟（2.6%）、头孢曲松（1%）、头孢他啶-阿维巴坦（99.6%）、替比培南（89%）、厄他培南（94.4%）、左氧氟沙星（26.6%）、甲氧苄啶-磺胺甲恶唑（40.2%）和磷霉素（96.8%）。头孢布烯-阿维巴坦对头孢菌素不敏感的分离菌显示出强效活性。
相似文献
1
Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of from outpatient centers and nursing homes across the United States (2022-2024).新型头孢布烯-阿维巴坦、头孢他啶-阿维巴坦及对照药物对来自美国各地门诊中心和疗养院的一组受试菌株的活性（2022 - 2024年）
Antimicrob Agents Chemother. 2025 May 7;69(5):e0186724. doi: 10.1128/aac.01867-24. Epub 2025 Apr 3.
2
Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing.选择合适的阿维巴坦浓度与头孢布烯联合用于肉汤微量稀释药敏试验。
Diagn Microbiol Infect Dis. 2022 Jun;103(2):115673. doi: 10.1016/j.diagmicrobio.2022.115673. Epub 2022 Mar 10.
3
Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program.西他滨-阿维巴坦对 ATLAS 全球监测计划中β-内酰胺酶阳性肠杆菌科的活性。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134622. doi: 10.1128/aac.01346-22. Epub 2023 Jan 5.
4
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).头孢他啶-阿维巴坦对全球尿路感染患者肠杆菌科的抗菌活性（2021 年）。
Eur J Clin Microbiol Infect Dis. 2023 Apr;42(4):453-459. doi: 10.1007/s10096-023-04562-4. Epub 2023 Feb 22.
5
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.产D组碳青霉烯酶菌血症中表型导向治疗的临床结局
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
6
Antibiotic susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing Enterobacterales: Low activity of cefiderocol against NDM-producing isolates.对新型抗生素的抗生素敏感性及产碳青霉烯酶肠杆菌科细菌的基因特征：头孢地尔对产NDM分离株的活性较低。
Int J Antimicrob Agents. 2025 Jun 18;66(4):107553. doi: 10.1016/j.ijantimicag.2025.107553.
7
Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States.替比培南及对照药物对美国不同门诊中心和疗养院肠杆菌科的抗菌活性。
Int J Antimicrob Agents. 2023 Mar;61(3):106733. doi: 10.1016/j.ijantimicag.2023.106733. Epub 2023 Jan 20.
8
Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Clinical Isolates.头孢他啶-阿维巴坦 30/20μg 药敏纸片法、Etest 法与肉汤微量稀释法检测临床分离株结果比较
Microbiol Spectr. 2022 Feb 23;10(1):e0109221. doi: 10.1128/spectrum.01092-21. Epub 2022 Jan 12.
9
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of and .2017 年中国抗菌药物监测网（CHINET）对临床分离的 和 的头孢他啶-阿维巴坦和头孢唑南-他唑巴坦活性研究结果。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02431-18. Print 2019 Apr.
10
Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales.美国医疗中心血流感染肠杆菌科的抗菌药物敏感性：多粘菌素类联合替加环素与碳青霉烯类耐药肠杆菌科抗菌药物的比较。
BMC Infect Dis. 2024 Nov 5;24(1):1242. doi: 10.1186/s12879-024-10133-5.
引用本文的文献
1
The Changing Landscape of Antibiotic Treatment: Reevaluating Treatment Length in the Age of New Agents.抗生素治疗的不断变化格局：在新型药物时代重新评估治疗时长。
Antibiotics (Basel). 2025 Jul 20;14(7):727. doi: 10.3390/antibiotics14070727.
本文引用的文献
1
Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales.肠杆菌科细菌对头孢替坦/阿维巴坦的突变耐药频率及机制
J Antimicrob Chemother. 2025 Mar 3;80(3):645-656. doi: 10.1093/jac/dkae452.
2
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.美国传染病学会2024年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2024 Aug 7. doi: 10.1093/cid/ciae403.
3
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies.治疗下尿路感染的临床前和早期临床开发中的疗法：从病原体到疗法。
Expert Opin Investig Drugs. 2024 Jul;33(7):677-698. doi: 10.1080/13543784.2024.2351509. Epub 2024 May 9.
4
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in .对获得性广谱β-内酰胺酶对单独或联合使用β-内酰胺酶抑制剂阿维巴坦和替加环素的口服青霉素类/碳青霉烯类（替比培南、舒巴坦、法罗培南）敏感性的影响。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0054723. doi: 10.1128/aac.00547-23. Epub 2023 Sep 5.
5
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).头孢他啶-阿维巴坦对全球尿路感染患者肠杆菌科的抗菌活性（2021 年）。
Eur J Clin Microbiol Infect Dis. 2023 Apr;42(4):453-459. doi: 10.1007/s10096-023-04562-4. Epub 2023 Feb 22.
6
Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States.替比培南及对照药物对美国不同门诊中心和疗养院肠杆菌科的抗菌活性。
Int J Antimicrob Agents. 2023 Mar;61(3):106733. doi: 10.1016/j.ijantimicag.2023.106733. Epub 2023 Jan 20.
7
Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program.西他滨-阿维巴坦对 ATLAS 全球监测计划中β-内酰胺酶阳性肠杆菌科的活性。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134622. doi: 10.1128/aac.01346-22. Epub 2023 Jan 5.
8
Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States.美国急诊科成年患者中肠杆菌科细菌所致复杂性尿路感染的流行病学
Open Forum Infect Dis. 2022 Jun 24;9(7):ofac315. doi: 10.1093/ofid/ofac315. eCollection 2022 Jul.
9
Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production.合成新旧β-内酰胺酶抑制剂的建议：鼓励进一步生产的综述
Pharmaceuticals (Basel). 2022 Mar 21;15(3):384. doi: 10.3390/ph15030384.
10
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担：系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
Zotero 插件